NCT00570999View on ClinicalTrials.gov

Palifermin After Haploidentical PBSCT

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

February 29, 2008

Study Completion Date

January 31, 2013

Conditions

Non-Hodgkin's Lymphoma or Hodgkin's DiseaseAcute LeukaemiaMyelodysplastic SyndromeChronic Myeloid LeukemiaOsteomyelofibrosis

Interventions

DRUG

Palifermin

60 mg/kg/day

OTHER

Placebo

1,2 mL once daily

Trial Locations (1)

97080

Dr Ruth Seggewiss, Würzburg

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

European Society for Blood and Marrow Transplantation

NETWORK